XNPT 7.95 Xenoport Inc $XNPT Hit a 52 week high of
Post# of 57
Posted On: 11/13/2014 2:34:03 PM
XNPT 7.95 Xenoport Inc $XNPT Hit a 52 week high of 7.95 Closing the day 09:45 at 7.95 +0.08 +1.02% With a day low of 7.87 and a total volume of 63,327.
XNPT Recent Posts: http://investorshangout.com/XenoPort-Inc-XNPT-55935/
XNPT Xenoport Inc Recent Headline News
52.4% Return Seen to Date on SmarTrend XenoPort Call (XNPT)
Comtex SmarTrend(R) - Wed Nov 12, 4:49PM CST
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 3 months, XenoPort has returned 52.37% as of today's recent price of $7.87.
XNPT: 8.08 (+0.21)
XenoPort's (XNPT) CEO Ron Barrett Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 2:03PM CST
XNPT: 8.08 (+0.21)
Can the Uptrend Continue for XenoPort (XNPT)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 6:33AM CST
Can the Uptrend Continue for XenoPort (XNPT)?
XNPT: 8.08 (+0.21)
XenoPort to Present at the Credit Suisse Healthcare Conference
Business Wire - Thu Nov 06, 12:09PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Credit Suisse Healthcare Conference in Phoenix, Arizona. The live presentation will occur at 8:30 a.m. Pacific Time (9:30 a.m. Mountain Time) on Wednesday, November 12, 2014. A replay of the presentation will also be available.
XNPT: 8.08 (+0.21)
XenoPort Has Returned 39.6% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Nov 05, 11:04AM CST
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 39.59% as of today's recent price of $7.21.
XNPT: 8.08 (+0.21)
XenoPort's (XNPT) CEO Ron Barrett on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 9:40PM CST
XNPT: 8.08 (+0.21)
XenoPort (XNPT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST
XNPT: 8.08 (+0.21)
XenoPort beats by $0.49, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:27PM CST
XNPT: 8.08 (+0.21)
XenoPort Reports Third Quarter Financial Results
Business Wire - Tue Nov 04, 3:07PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2014. Revenues for the third quarter were $31.1 million compared to $2.5 million for the same period in 2013. Revenues for the third quarter included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Reckitt Benckiser Pharmaceuticals, Inc. Net income for the third quarter was $8.3 million compared to a net loss of $18.8 million for the same period in 2013. At September 30, 2014, XenoPort had cash, cash equivalents and short-term investments of $113.4 million.
XNPT: 8.08 (+0.21)
XNPT, AMRS, GSAT, CRDC, IOSP, OKS Expected To Be Down After Next Earnings Releases
M2 - Mon Nov 03, 3:33AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, November 4th 2014 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Xenoport Inc (NASDAQ:XNPT), AMYRIS INC (NASDAQ:AMRS), Globalstar Inc (OTC:GSAT), Cardica Inc (NASDAQ:CRDC), INNOSPEC INC. (NASDAQ:IOSP), ONEOK PARTNERS, L.P. (NYSE:OKS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Tuesday:
AMRS: 2.82 (-0.11), IOSP: 43.80 (-0.43), OKE: 55.42 (-1.04), CRDC: 0.85 (-0.02), OKS: 47.99 (+0.01), GSAT: 2.81 (+0.06), XNPT: 8.08 (+0.21)
XenoPort Up 32.4% Since SmarTrend Uptrend Call (XNPT)
Comtex SmarTrend(R) - Wed Oct 29, 9:38AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 32.43% as of today's recent price of $6.84.
XNPT: 8.08 (+0.21)
XenoPort reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 10:53AM CDT
XNPT: 8.08 (+0.21)
XenoPort to Release Third Quarter Financial Results on November 4
Business Wire - Thu Oct 23, 9:00AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its third quarter financial results on November 4, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
XNPT: 8.08 (+0.21)
XenoPort Shares Up 22.6% Since SmarTrend's Buy Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Oct 22, 9:18AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 22.56% as of today's recent price of $6.33.
XNPT: 8.08 (+0.21)
Uptrend Call Working As XenoPort Stock Rises 20.2% (XNPT)
Comtex SmarTrend(R) - Tue Oct 14, 5:17PM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 20.23% as of today's recent price of $6.21.
XNPT: 8.08 (+0.21)
Commit To Buy XenoPort At $5, Earn 15.8% Annualized Using Options
StockOptionsChannel.com - Thu Oct 09, 10:29AM CDT
Investors eyeing a purchase of XenoPort Inc shares, but tentative about paying the going market price of $5.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
XNPT: 8.08 (+0.21)
Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 4.30 (-0.06), SNTS: (), OCRX: 5.59 (-0.01), ANAC: 31.52 (-0.25), XNPT: 8.08 (+0.21)
Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:55PM CDT
Xenoport, Inc. (XNPT) entered into a clinical trial collaboration agreement with the National Institute on Alcohol Abuse and Alcoholism, for a study that will evaluate HORIZANT as a potential treatment for alcohol use disorder (AUD).
CBPO: 66.55 (-2.18), CBM: 23.26 (-0.76), AMGN: 160.15 (-1.78), XNPT: 8.08 (+0.21)
XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston
Business Wire - Wed Sep 10, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829.
XNPT: 8.08 (+0.21)
XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
Business Wire - Tue Sep 09, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT.
XNPT: 8.08 (+0.21)
XNPT Recent Posts: http://investorshangout.com/XenoPort-Inc-XNPT-55935/
XNPT Xenoport Inc Recent Headline News
52.4% Return Seen to Date on SmarTrend XenoPort Call (XNPT)
Comtex SmarTrend(R) - Wed Nov 12, 4:49PM CST
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 3 months, XenoPort has returned 52.37% as of today's recent price of $7.87.
XNPT: 8.08 (+0.21)
XenoPort's (XNPT) CEO Ron Barrett Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 2:03PM CST
XNPT: 8.08 (+0.21)
Can the Uptrend Continue for XenoPort (XNPT)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 6:33AM CST
Can the Uptrend Continue for XenoPort (XNPT)?
XNPT: 8.08 (+0.21)
XenoPort to Present at the Credit Suisse Healthcare Conference
Business Wire - Thu Nov 06, 12:09PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Credit Suisse Healthcare Conference in Phoenix, Arizona. The live presentation will occur at 8:30 a.m. Pacific Time (9:30 a.m. Mountain Time) on Wednesday, November 12, 2014. A replay of the presentation will also be available.
XNPT: 8.08 (+0.21)
XenoPort Has Returned 39.6% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Nov 05, 11:04AM CST
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 39.59% as of today's recent price of $7.21.
XNPT: 8.08 (+0.21)
XenoPort's (XNPT) CEO Ron Barrett on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 9:40PM CST
XNPT: 8.08 (+0.21)
XenoPort (XNPT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST
XNPT: 8.08 (+0.21)
XenoPort beats by $0.49, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:27PM CST
XNPT: 8.08 (+0.21)
XenoPort Reports Third Quarter Financial Results
Business Wire - Tue Nov 04, 3:07PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2014. Revenues for the third quarter were $31.1 million compared to $2.5 million for the same period in 2013. Revenues for the third quarter included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Reckitt Benckiser Pharmaceuticals, Inc. Net income for the third quarter was $8.3 million compared to a net loss of $18.8 million for the same period in 2013. At September 30, 2014, XenoPort had cash, cash equivalents and short-term investments of $113.4 million.
XNPT: 8.08 (+0.21)
XNPT, AMRS, GSAT, CRDC, IOSP, OKS Expected To Be Down After Next Earnings Releases
M2 - Mon Nov 03, 3:33AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, November 4th 2014 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Xenoport Inc (NASDAQ:XNPT), AMYRIS INC (NASDAQ:AMRS), Globalstar Inc (OTC:GSAT), Cardica Inc (NASDAQ:CRDC), INNOSPEC INC. (NASDAQ:IOSP), ONEOK PARTNERS, L.P. (NYSE:OKS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Tuesday:
AMRS: 2.82 (-0.11), IOSP: 43.80 (-0.43), OKE: 55.42 (-1.04), CRDC: 0.85 (-0.02), OKS: 47.99 (+0.01), GSAT: 2.81 (+0.06), XNPT: 8.08 (+0.21)
XenoPort Up 32.4% Since SmarTrend Uptrend Call (XNPT)
Comtex SmarTrend(R) - Wed Oct 29, 9:38AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 32.43% as of today's recent price of $6.84.
XNPT: 8.08 (+0.21)
XenoPort reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 10:53AM CDT
XNPT: 8.08 (+0.21)
XenoPort to Release Third Quarter Financial Results on November 4
Business Wire - Thu Oct 23, 9:00AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its third quarter financial results on November 4, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
XNPT: 8.08 (+0.21)
XenoPort Shares Up 22.6% Since SmarTrend's Buy Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Oct 22, 9:18AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 22.56% as of today's recent price of $6.33.
XNPT: 8.08 (+0.21)
Uptrend Call Working As XenoPort Stock Rises 20.2% (XNPT)
Comtex SmarTrend(R) - Tue Oct 14, 5:17PM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 20.23% as of today's recent price of $6.21.
XNPT: 8.08 (+0.21)
Commit To Buy XenoPort At $5, Earn 15.8% Annualized Using Options
StockOptionsChannel.com - Thu Oct 09, 10:29AM CDT
Investors eyeing a purchase of XenoPort Inc shares, but tentative about paying the going market price of $5.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
XNPT: 8.08 (+0.21)
Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 4.30 (-0.06), SNTS: (), OCRX: 5.59 (-0.01), ANAC: 31.52 (-0.25), XNPT: 8.08 (+0.21)
Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:55PM CDT
Xenoport, Inc. (XNPT) entered into a clinical trial collaboration agreement with the National Institute on Alcohol Abuse and Alcoholism, for a study that will evaluate HORIZANT as a potential treatment for alcohol use disorder (AUD).
CBPO: 66.55 (-2.18), CBM: 23.26 (-0.76), AMGN: 160.15 (-1.78), XNPT: 8.08 (+0.21)
XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston
Business Wire - Wed Sep 10, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829.
XNPT: 8.08 (+0.21)
XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
Business Wire - Tue Sep 09, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT.
XNPT: 8.08 (+0.21)
(0)
(0)XenoPort Inc (XNPT) Stock Research Links
Scroll down for more posts ▼